Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

UKALL14: Rituximab improves EFS in B-ALL, but four doses not enough

Publish date:: January 15, 2020

Key clinical point: Adding rituximab to chemotherapy appears to improve EFS in B-ALL, but more than four doses are needed.

Major finding: EFS rates were 41.9% and 48.7% with SOC and SOC+rituximab, a significant difference.

Study details: The randomized, phase 3 UKALL14 trial of 577 patients.

Disclosures: Dr. Fielding is a consultant for Amgen, Novartis, Pfizer, and Incyte.

Citation:

Marks D et al. ASH 2019, Abstract 739.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

COVID-19–related outcomes poor for patients with hematologic disease in ASH registry,

Study: Complications from childhood ALL and its treatment are common, but can be managed,

All Specialties